Eosinophilic colitis with favorable response to vedolizumab.

Eosinophilic gastroenteritis is a rare, chronic inflammatory disease with eosinophil infiltration in the digestive tract. Treatment typically involves corticosteroids, but new therapies, including vedolizumab, are under evaluation. Vedolizumab inhibits lymphocyte migration to intestinal tissue, impacting eosinophil activity.

Insulin eye drops for treating corneal ulcer in a non-diabetic patient: regarding a case.

Corneal ulcers are included in a heterogeneous group of eye injuries. When  patients do not respond to treatment, including even corneal transplant, other  alternatives need to be explored.We present a case of a patient who suffered an accidental spillage from the  contents of a car battery.

Therapeutic drug monitoring of infliximab in spondyloarthritis. A review of the literature.

Available evidence indicates that a therapeutic drug monitoring strategy leads to major cost savings related to the anti-tumour necrosis factor-α therapy in both inflammatory bowel disease and rheumatoid arthritis (RA) patients, with no negative impact on efficacy. However, although the systematic use of therapeutic drug monitoring could potentially be beneficial and economically acceptable to drug dose optimization, it is not justifiable for all drugs. Infliximab (IFX) is a chimeric monoclonal immunoglobulin G1 targeting tumour necrosis factor.

Concordance between pharmacotherapeutic complexity calculated and perceived by HIV+ patients with antiretroviral treatment.

Objective: To determine the difference between the pharmacotherapeutic complexity index by Medication Regimen Complexity Index  and it's perceived by patients through a visual analogue scale in patients  HIV+ with antiretroviral treatment.

Method: Prospective, observational study of patients HIV+ > 18 years of age  with stable antiretroviral treatment in the last three months, followed up by  external consultations of pharmaceutical care between October´17 and February ´18. The main variable of the study was the concordance between the median of  the score obtained in the pharmacotherapeutic complexity perceived  by the patients using the visual analog scale whose range of values oscillates between 0-10, categorized in low complexity (0-1) and high  complexity (2-10), and the median of the score obtained for the theoretical  pharmacotherapeutic complexity using the Medication Regimen Complexity  Index tool whose ranges of values oscillate between 1 and infinity, categorized  in low complexity (0-11) and high complexity > 11.

Emergence of Inflammatory Bowel Disease During Treatment With Secukinumab.

Secukinumab is an anti-IL 17A monoclonal antibody currently licensed for the treatment of plaque psoriasis, psoriatic arthritis, and ankylosing spondylitis. However, although inflammatory bowel disease is a disorder with related immune characteristics, secukinumab has not proved to be effective in these diseases. In fact, negative results in a clinical trial designed to assess the efficacy of secukinumab in patients with Crohn's disease have been published.